In a major step forward for accessible brain health, the FDA has just cleared the first-ever blood test to help diagnose Alzheimer’s disease—and it could be a game changer for millions of Americans.

The new test, known as the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, provides a less invasive and more affordable alternative to PET scans and spinal taps. It works by analyzing two proteins in the blood that signal the presence of amyloid plaques in the brain—a key indicator of Alzheimer’s.

Until now, confirming Alzheimer’s often meant high-cost imaging or an uncomfortable spinal tap. With this new blood test, early detection could become much more accessible—especially for underserved communities that face barriers to specialty care.

Why is this a big deal? Because early diagnosis is critical. Alzheimer’s affects nearly 7 million Americans today—and that number is expected to nearly double by 2050. With this new test, we can better identify symptoms sooner and help people get the care and support they need earlier in the disease.

To learn more about how this breakthrough works and what it means for you and your loved ones, read the full story from the FDA here.

The National Minority Quality Forum has developed culturally tailored patient empowerment guides to educate and help patients confidently take control of their Alzheimer’s journey. Learn more.